Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Software Resilience | Explore SLP's robust software segment, showcasing 8% organic growth and a 10% increase in average revenue per customer, highlighting its essential role in pharmaceuticals |
Service Sector Challenges | Delve into the headwinds facing SLP's service segment, including client-driven delays and a significant contract cancellation impacting revenue forecasts |
Strategic Positioning | Learn how SLP maintains a competitive edge with its comprehensive software suite, trading at a premium compared to competitors despite recent market challenges |
Future Prospects | Discover SLP's revised outlook, with analyst price targets ranging from $28 to $41 per share, and potential opportunities arising from evolving FDA regulations |
Metrics to compare | SLP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLPPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.2x | −2.1x | −0.5x | |
PEG Ratio | 0.01 | −0.02 | 0.00 | |
Price/Book | 2.2x | 1.2x | 2.6x | |
Price / LTM Sales | 3.3x | 2.1x | 3.2x | |
Upside (Analyst Target) | 89.0% | 15.8% | 41.4% | |
Fair Value Upside | Unlock | 20.8% | 6.0% | Unlock |